Representative Cases

The firm has been actively involved in the following national antitrust class action and non-class action cases:

  • In re Buspirone Antitrust Litig., No. 1410, S.D.N.Y. ($220,000,000 recovery).
  • In re Cardizem CD Antitrust Litig., No. 1278, E.D.Mich. ($110,000,000 recovery).
  • In re Relafen Antitrust Litig., No. 01-12239, D.Mass. ($175,000,000 recovery).
  • In re Brand Name Prescription Drugs Antitrust Litig., No. 94 C 897, E.D.N.Y. (representation of 3,800 non-class independent retail pharmacy operations) (private settlements reached with many defendants).
  • In re Terazosin Hydrochloride Antitrust Litig., No. 1317, S.D. Fla. ($72,500,000 recovery).
  • In re Remeron Antitrust Litig., No. 03-CV-0085, D.N.J. ($75,000,000 recovery).
  • In re K-Dur Antitrust Litig., No. 1419, D.N.J. ($60,000,000 recovery).
  • In re TriCor Direct Purchaser Antitrust Litig., No. 05-340, D. Del. ($250,000,000 recovery).
  • In re Hypodermic Direct Purchaser Antitrust Litig., No. 05-1602, D.N.J. ($45,000,000 recovery).
  • Natchitoches Parish Hospital Service District et al v. Tyco International (US) et al., No. 05-cv-12024, D. Mass. ($32,500,000 recovery).
  • Louisiana Wholesale Drug Co., Inc. v. Abbott Laboratories, No. C 07-06118, N.D. Cal., ($52,000,000 recovery).
  • In re Modafinil Antitrust Litig., No. 06-1797, E.D. Pa. (recoveries totaling over $760,000,000).
  • In re Prograf Antitrust Litig., No. 1:11-MD-033242, U.S.D.C, D. Mass. ($98,000,000 recovery).
  • In re Lidoderm Antitrust Litig., No. 14-md-2521, N.D. Cal. ($166,000,000 recovery).
  • In re Aggrenox Antitrust Litig., No. 3:14-md-2516, D. Conn. ($146,000,000 recovery).
  • In re Neurontin Antitrust Litig., No. 02-1390, D.N.J. ($190,000,000 recovery).
  • In re Androgel Antitrust Litig., No. 1:09-md-2084-TWT, U.S.D.C, N.D Ga. (pending).
  • In re Novartis and Par Antitrust Litig., No. 1:18-cv-4361, U.S.D.C, S.D.N.Y. (pending).
  • Louisiana Wholesale Drug Co., Inc. v. Smithkline Beecham Corp., et al., No. 2:12-cv-995, D.N.J. (pending).
  • In re Mushrooms Antitrust Litig., No. 2:06-cv-620, U.S.D.C, E.D. Pa. (pending).
  • In re Namenda Antitrust Litig., 1:15-cv-7488, U.S.D.C, S.D.N.Y. (pending).
  • In re Opana ER Antitrust Litig., No. 2580, S.D.N.Y. (pending).
  • In re Suboxone Antitrust Litig., No. 2:13-md-2445, U.S.D.C, E.D. Pa. (pending).